Literature DB >> 14634803

Long-term outcome of patients with urea cycle disorders and the question of neonatal screening.

Claude Bachmann1.   

Abstract

UNLABELLED: With regard to the principles established for neonatal population screening, the question arises whether for patients with urea cycle disorders there is an accepted treatment which really affects the disease course and prognosis as compared to the natural history of these diseases. A retrospective study of 88 patients was performed. Based on questionnaires, the survival rate and neurodevelopmental outcome of patients treated with protein restriction alone was compared to the new therapy introduced in the 1980s with added citrulline/arginine, essential amino acids for improving the amino acid composition of the restricted natural protein and benzoate. Survival of patients with neonatal presentation was improved by the extensive therapy but this mostly at the cost of an increasing number of retarded patients. Long-term outcome did not differ significantly between the two treatments. Of all patients, 56% were symptomatic within 4 days of age and 67% within the 1st week. Thus a prevention of irreversible damage by neonatal screening on blood obtained at 3-4 days of life is questionable. Whether the benefit of obtaining a rapid diagnosis, e.g. for allowing proper counselling and prospective treatment, is acceptable for the parents of prospective patients remains open. The organisation of a dense network of specialised metabolic centres with sufficient staff and resources is a prior condition for any screening programme in order to ensure the rapid diagnosis, follow-up of treatment and counselling of a cumulative number of affected chronic patients needing this support. A commitment on a long-term basis by the institutions is needed in view of the health budget restrictions.
CONCLUSION: in the short term, the goal is to detect hyperammonaemic patients as early as possible with special emphasis on sick neonates. In practice, quantitative plasma ammonia determination without delay is recommended in any newborn for whom a sepsis work-up is considered and in children who refuse feeding or vomit and show alterations of consciousness and/or neurological symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634803     DOI: 10.1007/s00431-003-1347-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Prospective treatment of urea cycle disorders.

Authors:  N E Maestri; E R Hauser; D Bartholomew; S W Brusilow
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

Review 2.  Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

Authors:  R J Pollitt; A Green; C J McCabe; A Booth; N J Cooper; J V Leonard; J Nicholl; P Nicholson; J R Tunaley; N K Virdi
Journal:  Health Technol Assess       Date:  1997       Impact factor: 4.014

3.  Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation.

Authors:  Claude Bachmann
Journal:  Eur J Pediatr       Date:  2003-03-27       Impact factor: 3.183

4.  Long-term treatment of girls with ornithine transcarbamylase deficiency.

Authors:  N E Maestri; S W Brusilow; D B Clissold; S S Bassett
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

5.  Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing.

Authors:  A Tluczek; E H Mischler; P M Farrell; N Fost; N M Peterson; P Carey; W T Bruns; C McCarthy
Journal:  J Dev Behav Pediatr       Date:  1992-06       Impact factor: 2.225

6.  Liver transplantation in urea cycle disorders.

Authors:  J M Saudubray; G Touati; P Delonlay; P Jouvet; C Narcy; J Laurent; D Rabier; P Kamoun; D Jan; Y Revillon
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

7.  Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies.

Authors:  M Msall; M L Batshaw; R Suss; S W Brusilow; E D Mellits
Journal:  N Engl J Med       Date:  1984-06-07       Impact factor: 91.245

8.  Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan.

Authors:  T Uchino; F Endo; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  In vivo measurement of ureagenesis with stable isotopes.

Authors:  M Yudkoff; Y Daikhin; X Ye; J M Wilson; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

10.  Long-term survival of patients with argininosuccinate synthetase deficiency.

Authors:  N E Maestri; D B Clissold; S W Brusilow
Journal:  J Pediatr       Date:  1995-12       Impact factor: 4.406

  10 in total
  19 in total

1.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 2.  Brain imaging in urea cycle disorders.

Authors:  Andrea Gropman
Journal:  Mol Genet Metab       Date:  2010-02-13       Impact factor: 4.797

3.  Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders.

Authors:  Roland Posset; Angeles Garcia-Cazorla; Vassili Valayannopoulos; Elisa Leão Teles; Carlo Dionisi-Vici; Anaïs Brassier; Alberto B Burlina; Peter Burgard; Elisenda Cortès-Saladelafont; Dries Dobbelaere; Maria L Couce; Jolanta Sykut-Cegielska; Johannes Häberle; Allan M Lund; Anupam Chakrapani; Manuel Schiff; John H Walter; Jiri Zeman; Roshni Vara; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

4.  Favorable long-term outcome following severe neonatal hyperammonemic coma in a patient with argininosuccinate synthetase deficiency.

Authors:  Isabelle De Bie; Emmanuelle Lemyre; Marie Lambert
Journal:  JIMD Rep       Date:  2011-06-22

5.  Urea cycle disorders: brain MRI and neurological outcome.

Authors:  William R Bireley; Johan L K Van Hove; Renata C Gallagher; Laura Z Fenton
Journal:  Pediatr Radiol       Date:  2011-10-12

Review 6.  Recognition and diagnostic approach to acute metabolic disorders in the neonatal period.

Authors:  Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2011

Review 7.  Treatment strategies for acute metabolic disorders in neonates.

Authors:  Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2011

8.  Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study.

Authors:  Philippe M Campeau; Penelope J Pivalizza; Geoffrey Miller; Kim McBride; Saul Karpen; John Goss; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2010-02-19       Impact factor: 4.797

Review 9.  Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.

Authors:  A Cartagena; A N Prasad; C A Rupar; M Strong; M Tuchman; N Ah Mew; C Prasad
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

Review 10.  Neurological implications of urea cycle disorders.

Authors:  A L Gropman; M Summar; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-11-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.